home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

56.75 -0.27 (-0.47%)

Streaming Delayed Price Updated: 3:59 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

35 36 Next >

Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says ↗

November 16, 2022

Via Benzinga

FDA Gives Emergency Use Nod To Roche's Monkeypox Test ↗

November 16, 2022

Via Benzinga

Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage ↗

November 15, 2022

Via Benzinga

Roche Inks Second Drug Discovery Deal With Jnana Therapeutics ↗

November 15, 2022

Via Benzinga

The OTCQB Venture Market Records 4 Months Of Consecutive Volume Increases In OTC Market Group’s Most-Active List In October

November 15, 2022

The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 8.13% in October — its second-largest monthly increase in 2022. The Fidelity NASDAQ Composite Index ETF (NASDAQ: ONEQ) and the SPDR Dow Jones...

Via TheNewswire.com

Topics ETFs Stocks

Biogen To Report Q3 Earnings: Here's What To Expect ↗

October 21, 2022

Biogen will report third-quarter 2022 results on Oct 25, before market open.

Via Talk Markets

FDA Grants Conditional Approval To First Antibody Drug Conjugate From ImmunoGen For Pretreated Ovarian Cancer ↗

November 15, 2022

Via Benzinga

Why Is Cassava Sciences (SAVA) Stock Up Today? ↗

November 14, 2022

Today's big move in Cassava Sciences and SAVA stock has many investors watching this company's trials closer than ever.

Via InvestorPlace

Eli Lilly's Twitter Fiasco Continues As Drugmaker Reportedly Pulls 'Millions' In Twitter Ads ↗

November 14, 2022

The fallout from a fake account continued Monday as Lilly reportedly pulled Twitter ads.

Via Investor's Business Daily

Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers ↗

November 14, 2022

Via Benzinga

Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies

November 14, 2022

FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 14, 2022 – USA News Group – English actor, comedian and Monty Python alumnus Eric Idle credits early detection for his...

Via FinancialNewsMedia

Why Is Biogen (BIIB) Stock Up Today? ↗

November 14, 2022

Biogen (BIIB) stock is rising higher on Monday after Roche's (RHHBY) Alzheimer's drug didn't perform well in a clinical trial.

Via InvestorPlace

Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others ↗

November 14, 2022

Biogen rose on Roche's Alzheimer's failure as a potential competitor drops off the map.

Via Investor's Business Daily

The OTCQB Venture Market Records 4 Months Of Consecutive Volume Increases In OTC Market Group's Most-Active List In October ↗

November 14, 2022

The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 8.13% in October — its second-largest monthly increase in 2022.

Via Benzinga

Roche's Another Alzheimer's Hopeful Flops In Phase 3 Program, Second Trial Setback Within Months ↗

November 14, 2022

Via Benzinga

Nasdaq, S&P 500 Futures Pullback At Start Of New Trading Week As Rate Fears Return To Haunt; AMD, Tesla, Biogen, Eli Lilly, JD In Focus ↗

November 14, 2022

The major U.S. index futures are pointing to a moderately lower opening on Wall Street on Monday, as optimism following a tamer inflation data gives way to apprehension. The yield on the benchmark...

Via Benzinga

Why Shares Of Eli Lilly And Biogen Are Rallying Today ↗

November 14, 2022

Shares of Biogen Inc. (NASDAQ: BIIB) and Eli Lilly & Co. (NYSE: LLY) are rallying in premarket trading on Monday despite the negative broader market sentiment.

Via Benzinga

Genentech Provides Update on Phase III GRADUATE Program Evaluating Gantenerumab in Early Alzheimer’s Disease

November 14, 2022

From Genentech

Via Business Wire

Genentech to Present Data at ASH 2022 Showcasing Strength of Hematology Portfolio and Expanding Into New Areas to Address More Patient Needs

November 03, 2022

From Genentech

Via Business Wire

6 ETFs That Are All You Need for Retirement ↗

October 30, 2022

These yield-producing stock and bond funds are all down less than the S&P 500 this year.

Via The Motley Fool

15 Global Psychedelics Executives To Keep An Eye On In 2022 ↗

October 28, 2022

As the global psychedelics industry booms, with companies going public, major financings being announced, and celebrities and big investors getting on board, Benzinga has decided to put together a list...

Via Benzinga

Most Active On The OTC Markets In September – A Look Back As October Comes To A Close

October 28, 2022

By Jad Malaeb, Benzinga

Via News Direct

Topics ETFs Stocks

Most Active On The OTC Markets In September – A Look Back As October Comes To A Close

October 28, 2022

The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) declined by 9.62% in September – its largest decline in 2022. The Fidelity NASDAQ Composite Index ETF (NASDAQ: ONEQ) and the SPDR Dow Jones Industrial Average...

Via TheNewswire.com

Topics ETFs Stocks

Most Active On The OTC Markets In September – A Look Back As October Comes To A Close ↗

October 27, 2022

The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) declined by 9.62% in September – its largest decline in 2022.

Via Benzinga

Positive Topline Phase III Results Show Genentech’s Vabysmo Improved Vision for People Living With Retinal Vein Occlusion (RVO)

October 27, 2022

From Genentech

Via Business Wire

Early Treatment With Genentech’s Ocrevus (ocrelizumab) Leads to Reduced Disease Progression and Healthcare Costs; Nine-Year Safety Data Reinforce Favorable Benefit-Risk Profile

October 26, 2022

From Genentech

Via Business Wire

Analyst Bullish On SQZ Biotech's Technology For Solving Cell Therapy Challenges ↗

October 20, 2022

Via Benzinga

Genentech to Present New Ocrevus (ocrelizumab) Data in Multiple Sclerosis and Continued Research Into Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2022

October 19, 2022

From Genentech

Via Business Wire

Roche Posts Lower Quarterly Sales As Demand For COVID Products Slide ↗

October 18, 2022

Via Benzinga

Market Sentiment Improves Amid Earnings Season ↗

October 18, 2022

The fourth quarter started on a sour note as geopolitical tensions and recession fears triggered a risk-averse mood, but earnings season has started since then, focusing market participants’ attention...

Via Talk Markets

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com